Our client has a key legacy asset in hematology which faces increasing pressure from generic forms of an alternative medication across multiple lines of therapy in EU5.
Eradigm used analogue benchmarking to evaluate the potential impact on our client’s drug sales, and identified optimal market-specific and cross-EU pricing and non-pricing strategies to preserve value for payers.
